OKYO Pharma director granted 300,000 shares

OKYO Pharma Ltd director and 10% owner Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock.

Accepted by SEC EDGAR 06/10/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd director and 10% owner Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock. The shares were received as a grant or award at a reference price of $1.72 per share and are held through Panetta Partners Limited.

Following this transaction, indirect holdings associated with Cerrone total 10,826,416 shares of OKYO Pharma common stock, indicating this was a relatively small addition to an already large position.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider CERRONE GABRIELE M

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	300,000	$1.72	$516K

Holdings After Transaction: COMMON STOCK — 10,826,416 shares (Indirect, Via Panetta Partners Limited)

Key Figures

Shares granted: 300,000 shares Grant reference price: $1.72 per share Post-transaction holdings: 10,826,416 shares

3 metrics

Shares granted 300,000 shares Grant, award, or other acquisition of common stock

Grant reference price $1.72 per share Price per share for the 300,000-share award

Post-transaction holdings 10,826,416 shares Indirect common stock holdings following the transaction

Key Terms

Grant, award, or other acquisition, indirect ownership, Panetta Partners Limited

3 terms

Grant, award, or other acquisition financial

"The transaction is classified as a grant, award, or other acquisition"

indirect ownership financial

"The shares are held as indirect ownership via Panetta Partners Limited"

Panetta Partners Limited financial

"The shares were held indirectly through Panetta Partners Limited"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OKYO (OKYO) disclose in this Form 4?

OKYO Pharma disclosed that Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock. The transaction is classified as a grant or award, rather than an open-market purchase, and was executed at a reference price of $1.72 per share.

Who is Gabriele M. Cerrone in relation to OKYO (OKYO)?

Gabriele M. Cerrone is identified as both a director and a ten percent owner of OKYO Pharma. His reported holdings, including this transaction, reflect a significant ownership stake, which can align his interests with other shareholders over the longer term.

How many OKYO (OKYO) shares does Cerrone hold after this transaction?

After the reported grant of 300,000 shares, indirect holdings associated with Gabriele M. Cerrone total 10,826,416 shares of OKYO Pharma common stock. This figure shows that the new grant is a small addition compared with his existing position.

Was the OKYO (OKYO) insider transaction a market purchase or a grant?

The filing classifies the 300,000-share transaction as a grant, award, or other acquisition, not an open-market purchase. That means the shares were received as part of a non-market arrangement, such as compensation or a similar award, at a reference price of $1.72.

How are the newly acquired OKYO (OKYO) shares held by Cerrone?

The filing indicates the 300,000 newly acquired shares are held indirectly through Panetta Partners Limited. This reflects an indirect ownership structure, where the economic interest is associated with Cerrone but the shares are registered in the name of that entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CERRONE GABRIELE M

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	06/08/2026		A		300,000	A	$1.72	10,826,416	I	Via Panetta Partners Limited

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gabriele M. Cerrone	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)